A recent Phase 3 study conducted by Merck & Co. has demonstrated positive outcomes for patients with an advanced form of bladder cancer who were treated with Keytruda, the company’s renowned cancer drug.
Merck announced that the study successfully achieved its primary objective, which focused on disease-free survival in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma after undergoing surgery. This is a significant milestone, as up to half of bladder cancer patients who undergo surgery experience a recurrence within one year. The findings suggest that Keytruda has the potential to prevent this recurrence.
The study will continue evaluating its other primary objective, which concerns overall survival rates.
Keytruda, a groundbreaking cancer drug designed to activate a patient’s immune system against tumors, is currently being tested in various trials targeting different types of cancers and treatment settings. The drug has already received approvals for numerous indications worldwide and has achieved extraordinary sales exceeding $12 billion in the first half of 2023.
This exciting development brings hope to bladder cancer patients and further establishes Keytruda as a promising treatment option.
